IMCC Stock Analysis: Buy, Sell, or Hold?
IMCC - IM Cannabis Corp. Common Shares
$0.38
-0.03 (-8.09%)
▼
5d:
-37.46%
30d:
-48.02%
90d:
-72.83%
WAIT
LOW Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: Mar 30, 2026
0d
Get Alerted When IMCC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: IMCC is down 37.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: IMCC is down 37.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: IMCC is currently trading at $0.38, which is considered oversold relative to its 30-day fair value range of $0.56 to $0.84.
Technical Outlook: Technically, IMCC is in a strong downtrend. Immediate support is located at $0.30, while resistance sits at $0.80. Short-term momentum is weak, with the stock down 8.1% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.22 (+1915.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, IMCC is in a strong downtrend. Immediate support is located at $0.30, while resistance sits at $0.80. Short-term momentum is weak, with the stock down 8.1% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.22 (+1915.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$0.56 -
$0.84
Company Quality Score
37/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-8.1%)
- BULLISH: Trading 1915.0% below Wall St target ($8.22)
- WARNING: Recommendation downgraded due to -37.5% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$0.56 -
$0.84
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$0.30
Resistance Level
$0.80
Current Trend
Strong Downtrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
42.37
Wall Street Target
$8.22
(+1915.0%)
Revenue Growth (YoY)
-0.2%
Profit Margin
-9.0%
Share & Embed Analysis
Last updated: March 31, 2026 11:25 AM ET
Data refreshes hourly during market hours. Next update: 12:24 PM
Data refreshes hourly during market hours. Next update: 12:24 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IMCC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$178 | 63 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$151 | 55 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$91 | 55 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$21 | 63 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 56 HOLD |
